KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Equity (2016 - 2025)

Nektar Therapeutics has reported Return on Equity over the past 15 years, most recently at 1.78% for Q4 2025.

  • Quarterly results put Return on Equity at 1.78% for Q4 2025, up 39.0% from a year ago — trailing twelve months through Dec 2025 was 1.78% (up 39.0% YoY), and the annual figure for FY2025 was 2.06%, down 82.0%.
  • Return on Equity for Q4 2025 was 1.78% at Nektar Therapeutics, up from 3.72% in the prior quarter.
  • Over the last five years, Return on Equity for NKTR hit a ceiling of 22.04% in Q2 2025 and a floor of 3.72% in Q3 2025.
  • Median Return on Equity over the past 5 years was 0.85% (2022), compared with a mean of 0.2%.
  • Peak annual rise in Return on Equity hit 2109bps in 2025, while the deepest fall reached -538bps in 2025.
  • Nektar Therapeutics' Return on Equity stood at 0.71% in 2021, then crashed by -32bps to 0.94% in 2022, then surged by 99bps to 0.01% in 2023, then tumbled by -26202bps to 2.17% in 2024, then rose by 18bps to 1.78% in 2025.
  • The last three reported values for Return on Equity were 1.78% (Q4 2025), 3.72% (Q3 2025), and 22.04% (Q2 2025) per Business Quant data.